Alves et al., 2003 - Google Patents
Pathogenesis of rabies virus by ERA and PV strains administered orally in hamsters (M. auratus)Alves et al., 2003
View HTML- Document ID
- 6216973507422123065
- Author
- Alves L
- Soares R
- Cortez A
- Richtzenhain L
- Ito F
- Publication year
- Publication venue
- Brazilian Journal of Veterinary Research and Animal Science
External Links
Snippet
Hamsters orally inoculated with ERA and PV strains of rabies virus were sacrificed at 24, 48, 72 hours, 21 and 30 days after inoculation. Brain fragments were examined by Fluorescent Antibody test (FAT) and heminested PCR (hn-PCR). Fragments from stomach, blood, heart …
- 241000699800 Cricetinae 0 title abstract description 39
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goatley et al. | A pool of eight virally vectored African swine fever antigens protect pigs against fatal disease | |
| Arias et al. | Approaches and perspectives for development of African swine fever virus vaccines | |
| US20210308257A1 (en) | IMMUNOGENIC COMPOSITION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) | |
| Feng et al. | Virulent avian infectious bronchitis virus, People’s Republic of China | |
| US8647637B2 (en) | Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs | |
| Ahmadivand et al. | VP2 (PTA motif) encoding DNA vaccine confers protection against lethal challenge with infectious pancreatic necrosis virus (IPNV) in trout | |
| NO20180601A1 (en) | Isolated canine influenza A virus capable of infecting a canine animal, isolated polynucleotide comprising a nucleotide sequence and polynucleotide expression construct. | |
| Liang et al. | Understanding the research advances on lumpy skin disease: A comprehensive literature review of experimental evidence | |
| Baillon et al. | The viral hemorrhagic septicemia virus (VHSV) markers of virulence in rainbow trout (Oncorhynchus mykiss) | |
| Xu et al. | A effective DNA vaccine against diverse genotype J infectious hematopoietic necrosis virus strains prevalent in China | |
| Lu et al. | Evaluation of the infectivity, length of infection, and immune response of a low-pathogenicity H7N2 avian influenza virus in specific-pathogen-free chickens | |
| Diaz-San Segundo et al. | Poly ICLC increases the potency of a replication-defective human adenovirus vectored foot-and-mouth disease vaccine | |
| Miao et al. | Immunogenicity in rabbits of virus-like particles from a contemporary rabbit haemorrhagic disease virus Type 2 (GI. 2/RHDV2/b) isolated in the Netherlands | |
| Wellenberg et al. | Presence of European bat lyssavirus RNAs in apparently healthy Rousettus aegyptiacus bats | |
| Geerligs et al. | Efficacy and safety of an attenuated live QX-like infectious bronchitis virus strain as a vaccine for chickens | |
| CN106244602A (en) | A kind of carry two G genes and the recombinant rabies virus of VP2 gene and application thereof | |
| WO2021254473A1 (en) | Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (sars-cov-2) | |
| Uddbäck et al. | PB1 as a potential target for increasing the breadth of T-cell mediated immunity to Influenza A | |
| JP2022502513A (en) | H52 IBV vaccine with heterologous peplomer | |
| Alves et al. | Pathogenesis of rabies virus by ERA and PV strains administered orally in hamsters (M. auratus) | |
| Yang et al. | Safety and immunogenicity of recombinant rabies virus (ERAGS) in mice and raccoon dogs | |
| Gelb Jr et al. | Characterization of infectious bursal disease viruses isolated in 2007 from Delmarva commercial broiler chickens | |
| ALVES et al. | auratus | |
| Alhaji Saganuwan | Protection of SARS-CoV-2 trial vaccines in human is a function of the viral genomes | |
| US20240197862A1 (en) | Immunogenic compositions and methods for immunization against variants of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |